enVVeno Medical Corp
NVNO0.355USD
+0.013+3.74%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
7.17MMarket Cap
LossP/E TTM
More Details of enVVeno Medical Corp Company
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
enVVeno Medical Corp Info
Ticker SymbolNVNO
Company nameenVVeno Medical Corp
IPO dateMay 31, 2018
CEOBerman (Robert A)
Number of employees37
Security typeOrdinary Share
Fiscal year-endMay 31
Address70 Doppler
CityIRVINE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92618
Phone19492612900
Websitehttps://envveno.com/
Ticker SymbolNVNO
IPO dateMay 31, 2018
CEOBerman (Robert A)
Company Executives of enVVeno Medical Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
97.44K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
11.15K
+7.73%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
97.44K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
11.15K
+7.73%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Satterfield (Thomas A Jr)
9.02%
Perceptive Advisors LLC
8.70%
Kingdon Capital Management, L.L.C.
6.72%
The Vanguard Group, Inc.
4.26%
CM Management, LLC
2.97%
Other
68.33%
Shareholders
Shareholders
Proportion
Satterfield (Thomas A Jr)
9.02%
Perceptive Advisors LLC
8.70%
Kingdon Capital Management, L.L.C.
6.72%
The Vanguard Group, Inc.
4.26%
CM Management, LLC
2.97%
Other
68.33%
Shareholder Types
Shareholders
Proportion
Individual Investor
10.76%
Investment Advisor
10.13%
Private Equity
8.70%
Hedge Fund
7.28%
Investment Advisor/Hedge Fund
1.91%
Research Firm
1.34%
Venture Capital
0.21%
Other
59.67%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
76
5.69M
28.14%
-667.58K
2025Q2
75
3.80M
19.76%
-3.06M
2025Q1
73
3.82M
21.80%
-3.21M
2024Q4
75
4.44M
25.31%
-1.95M
2024Q3
71
5.27M
30.14%
+688.15K
2024Q2
65
3.79M
29.68%
-1.51M
2024Q1
67
4.10M
32.04%
-789.97K
2023Q4
59
4.71M
36.59%
+2.14M
2023Q3
57
2.68M
28.24%
-1.00M
2023Q2
55
2.71M
28.61%
-1.36M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Perceptive Advisors LLC
1.28M
6.68%
+1.28M
--
Jun 30, 2025
Kingdon Capital Management, L.L.C.
1.36M
7.06%
+500.00K
+58.19%
Sep 02, 2025
The Vanguard Group, Inc.
698.34K
3.63%
+97.43K
+16.21%
Jun 30, 2025
Westside Investment Management, LLC
279.52K
1.45%
+20.48K
+7.90%
Jun 30, 2025
Geode Capital Management, L.L.C.
199.51K
1.04%
+2.21K
+1.12%
Jun 30, 2025
J.P. Morgan Securities LLC
182.30K
0.95%
-11.91K
-6.13%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Date
Type
Ratio
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
FAQs
Who are the top five shareholders of enVVeno Medical Corp?
The top five shareholders of enVVeno Medical Corp are:
Perceptive Advisors LLC holds 1.28M shares, accounting for 6.68% of the total shares.
Kingdon Capital Management, L.L.C. holds 1.36M shares, accounting for 7.06% of the total shares.
The Vanguard Group, Inc. holds 698.34K shares, accounting for 3.63% of the total shares.
Westside Investment Management, LLC holds 279.52K shares, accounting for 1.45% of the total shares.
Geode Capital Management, L.L.C. holds 199.51K shares, accounting for 1.04% of the total shares.
Perceptive Advisors LLC holds 1.28M shares, accounting for 6.68% of the total shares.
Kingdon Capital Management, L.L.C. holds 1.36M shares, accounting for 7.06% of the total shares.
The Vanguard Group, Inc. holds 698.34K shares, accounting for 3.63% of the total shares.
Westside Investment Management, LLC holds 279.52K shares, accounting for 1.45% of the total shares.
Geode Capital Management, L.L.C. holds 199.51K shares, accounting for 1.04% of the total shares.
What are the top three shareholder types of enVVeno Medical Corp?
The top three shareholder types of enVVeno Medical Corp are:
Satterfield (Thomas A Jr)
Perceptive Advisors LLC
Kingdon Capital Management, L.L.C.
Satterfield (Thomas A Jr)
Perceptive Advisors LLC
Kingdon Capital Management, L.L.C.
How many institutions hold shares of enVVeno Medical Corp (NVNO)?
As of 2025Q3, 76 institutions hold shares of enVVeno Medical Corp, with a combined market value of approximately 5.69M, accounting for 28.14% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 8.37%.
What is the biggest source of revenue for enVVeno Medical Corp?
In --, the -- business generated the highest revenue for enVVeno Medical Corp, amounting to -- and accounting for --% of total revenue.
